Concord Medical Services Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was €-3.42.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.12.
During the past 3 years, the average EBIT per Share Growth Rate was 23.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Concord Medical Services Holdings's EBIT per Share or its related term are showing as below:
FRA:C2C'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -54.7 Med: -12.25 Max: 23.3
Current: 23.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Concord Medical Services Holdings was 23.30% per year. The lowest was -54.70% per year. And the median was -12.25% per year.
FRA:C2C's 3-Year EBIT Growth Rate is ranked better than 66.22% of 527
companies
in the Healthcare Providers & Services industry
Industry Median: 11.9
vs FRA:C2C: 23.30
Concord Medical Services Holdings (FRA:C2C) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Concord Medical Services Holdings EBIT per Share Related Terms
Concord Medical Services Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Services Holdings EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Medical Services Holdings (FRA:C2C) has a EBIT per Share of €-6.12 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Concord Medical Services Holdings and its competitors. According to the industry distribution chart, Concord Medical Services Holdings ranks #178 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 33.8%.
Is Concord Medical Services Holdings' EBIT per Share too high?
Concord Medical Services Holdings' current EBIT per Share is €-6.12. Based on the distribution chart, Concord Medical Services Holdings ranks #178 out of 527 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' EBIT per Share compare to CCEL and GBCS?
According to the Healthcare Providers & Services industry distribution chart, Concord Medical Services Holdings ranks #178 out of 527 companies for EBIT per Share. This puts Concord Medical Services Holdings in the upper half of its industry. The industry median EBIT per Share is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.90, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Concord Medical Services Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Services Holdings's current EBIT per Share is €-6.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current EBIT per Share of €-6.12. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current EBIT per Share is €-6.12. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current EBIT per Share is €-6.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued.
The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.
Key valuation signals for FRA:C2C:
EBIT per Share: €-6.12
GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Medical Services Holdings Business Description
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score
Get the complete analysis for FRA:C2C
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C2C has been successfully added to your 
